Alivus Life Sciences Limited has informed the Exchange regarding a press release dated May 15, 2025, titled "Press Release".
ALIVUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Alivus Life Sciences (formerly Glenmark Life Sciences) reported Q4FY25 revenue from operations of Rs. 649.6 crore, up 21.1% YoY and 1.2% QoQ. Full-year FY25 revenue grew 4.5% YoY to Rs. 2,386.9 crore, or 7.1% on a normalised basis after stripping out last year's PLI benefit. Q4FY25 EBITDA surged 44.2% YoY to Rs. 208.5 crore, with EBITDA margins expanding 520 bps to 32.1%; FY25 EBITDA margin held steady at 30% despite the absence of PLI benefits. FY25 PAT came in at Rs. 485.7 crore (margin 20.3%), and the company generated free cash flow of Rs. 232.8 crore, ending the year debt-free with Rs. 548.7 crore in cash and equivalents. Capex is in progress at the Solapur site (Phase 1, 200 KL), and cumulative DMF/CEP filings stood at 561 as of March 31, 2025.
Strong Q4 revenue growth, healthy margin expansion, and a debt-free, cash-rich balance sheet signal operational resilience and room for future capacity-led growth — likely a positive read for shareholders, though FY25 headline growth was modest without the PLI tailwind.